First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Teva Pharmaceutical Industries Ltd.

    TEVA · 12 developments mapped · last assessed 2026-09-19

    Market Ontology has mapped 12 macro, policy, and market developments to Teva Pharmaceutical Industries Ltd. since 2026-08-26. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for TEVA yet, so no modelled value is shown. The TEVA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run TEVA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for TEVA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity

      Direct positive impact on UZEDY sales and market share due to demonstrated superior real-world outcomes, potentially leading to increased prescriptions and payer preference.

      · Moves uzedy peak sales estimates, market share for long acting injectables in schizophrenia/bipolar i, future r&d allocation for similar real world evidence studies

    • Open question

      Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms

      Potential for increased competition in neurological disorder treatments, or opportunities for late-stage development/commercialization partnerships.

      · Moves market share assumptions, pipeline valuation

    What changed, by assumption

    Uzedy peak sales estimates
    • 2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment Continuity
    • 2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost Reductions
    Uzedy sales growth rate
    • 2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting Injectables
    • 2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costs
    Uzedy sales forecasts
    • 2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity
    • 2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare Utilization
    Cost of debt
    • 2026-09-07Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 Debt
    • 2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 Debt
    Uzedy sales forecast
    • 2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantage

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-09-11Cost of capitalBullishHigher cost-of-debt tranche lifts blended WACC.0.70
    2026-09-11Interest expenseBullishHigh-yield coupon materially raises interest burden.0.70
    2026-09-11Net debtBullishSub-IG debt raise increases leverage and net debt.0.70

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-19Teva Highlights Real-World Data Demonstrating UZEDY Superiority in Treatment ContinuityBullish1-3m0.80
    2026-09-19Teva presents real-world data showing UZEDY treatment continuity advantageBullish1-3m0.70
    2026-09-19Teva real-world data demonstrates UZEDY reduces emergency care and medical costsBullish3-12m0.70
    2026-09-19Teva Real-World Data Shows UZEDY Superiority in Schizophrenia ContinuityBullish1-3m0.80
    2026-09-19Teva Clinical Evidence Highlights UZEDY Treatment Retention and Cost ReductionsBullish3-12m0.80
    2026-09-19Teva Real-World Data Shows UZEDY Lowers Emergency Healthcare UtilizationBullish1-3m0.80
    2026-09-19Teva Real-World Study Shows UZEDY Outperforms Long-Acting InjectablesBullish1-3m0.80
    2026-09-16NRx Pharmaceuticals Reports FDA Reclassification of Ketamine Amendment to Minor Amendmentwatch3-12m0.20
    2026-09-07Teva launches EUR and USD senior notes to refinance high-coupon 2028-2029 debtBullish1-3m0.70
    2026-09-07Teva Launches EUR and USD Senior Notes Offering to Redeem 2028-2029 DebtBullish1-3m0.70
    2026-09-07Teva Launches Multi-Currency Senior Notes to Refinance High-Coupon 2028-2029 DebtBullish1-3m0.80
    2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firmswatch3-12m0.40